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Transferable plasmid mediating resistance to multiple antimicrobial
agents in Klebsiella pneumoniae isolates in Greece
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Medicine, University of Athens Medical School, Athens, Greece
Objective To investigate the underlying resistance mechanisms in 10 Klebsiella pneumo-
niae isolates.
Methods Ten K. pneumoniae strains according to distinct bacteriocin typing and REP-
PCR, were examined for their plasmid content, their ability to transfer their resistance to
aminoglycosides and third-generation cephalosporins, and their production of amino-
glycoside-modifying enzymes and b-lactamases.
Results Transfer of resistance to the above-mentioned antibiotics as well as to co-
trimoxazole and tetracycline in Escherichia coli strain RC 85 at a frequency of 5–106
was achieved for all strains by conjugation. Similar strains harbor a self-transferable
multiresistant plasmid (80 kb) with similar EcoRI and HindIII restriction patterns. This
plasmid encodes an extended-spectrum b-lactamase which confers high-level resistance
to third-generation cephalosporins and aztreonam. It produces SHV-5 b-lactamase, as
demonstrated by isoelectric focusing and DNA sequencing. Aminoglycoside resistance
was co-transferred, and AAC(60)-I, mediating resistance to gentamicin, tobramycin,
netilmicin and amikacin, and AAC(3)-I, mediating resistance to gentamicin and siso-
mycin, were encoded in all isolates and their transconjugants, while APH(30)-I, mediating
resistance to kanamycin and neomycin, was encoded in seven strains.
Conclusions It appears that a multiresistant transferable plasmid encoding the SHV-5 b-
lactamase, causing unusually high resistance to ceftazidime and aztreonam, and the
combination AAC(60)-IþAAC(3)-I of acetylating enzymes causing, also resistance to all
clinically available aminoglycosides, is established in K. pneumoniae in Greece.
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I N T R O D U C T I O N
Klebsiella pneumoniae strains, multiresistant to
aminoglycosides, ureidopenicillins, broad-spec-
trum cephalosporins and monobactams, pose a
serious epidemiologic and therapeutic problem
in Greek hospitals. Since their recognition, isolates
of K. pneumoniae producing extended-spectrum
b-lactamases (ESBLs) have been a major cause of
concern worldwide [1]. Most ESBLs are plasmid-
encoded enzymes derived from TEM- or SHV-type
b-lactamases by one or more amino acid substitu-
tions which confer resistance to broad-spectrum
cephalosporins [2]. SHV ESBLs have been termed
SHV-2 through SHV-26, including an SHV-2
variant, SHV-2a [3]. An inhibitor-resistant enzyme
was described, termed SHV-10, derived from an
SHV-5 variant (SHV-9) [4,5], which retained its
ability to hydrolyze penicillins, although its activ-
ity against cephalosporins was drastically reduced
[5]. Data from 55 hospitals in Greece showed
high resistance rates in K. pneumoniae not only to
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ceftazidime (31%) and aztreonam (30%) but also to
aminoglycosides (30% to netilmicin) [6]. These
findings, as well as the fact that an extended
broad-spectrum b-lactamase (SHV-5 type) respon-
sible for ceftazidime resistance was discovered
11 years before in K. pneumoniae isolates from
Greece [7], stimulated our interest in searching
for resistance mechanisms in K. pneumoniae strains
multiresistant to all aminoglycosides and third-
generation cephalosporins.
This was very important in order to deal with
the difficult therapeutic problem of K. pneumoniae
infections, since empirical treatment of nosocomial
infections in most Greek tertiary hospitals is
usually initiated with a combination of a cepha-
losporin plus an aminoglycoside.
M A T E R I A L S A N D M E T H O D S
Bacterial strains
The ten K. pneumoniae clinical iso1ates used in the
present study were isolated from patients with
urinary, lung or abdominal infections hospitalized
in four different Greek tertiary hospitals located in
Athens. The strains were identified as K. pneumoniae
by the API20E system (Merieux, Marcy-l0Etoile,
France). K. pneumoniae strain 160, producing b-
lactamase SHV-5 (pI 8.2), was used as reference
strain for b-lactamase determination [8]. Escheri-
chia coli RC85 R– K12 strain resistant to rifampicin
(MIC> 128 mg/L) was used as recipient strain in
mating experiments. E. coli strain MXR containing
plasmid pULB113 (68 kb) was used as reference
strain for plasmid DNA isolation [9].
Antibiotics
Disks for agar diffusion tests were purchased from
Diagnostics Pasteur, Marnes la Coquette, France.
Antibiotic powders were provided as follows:
ceftazidime, Glaxo Wellcome, UK; cefotaxime,
Hoechst-Roussel, Greenford, Puteaux, France; cef-
triaxone, Hoffman-La Roche, Basel, Switzerland;
cefuroxime, Glaxo Wellcome UK; aztreonam, Bris-
tol-Myers Squibb, Syracuse, NY, USA; imipenem,
Merck Research Laboratories, Elkton, VA, USA;
meropenem, Zeneca Pharmaceuticals, Maccles-
field, UK; clavulanic acid, SmithKline Beecham,
Worthing, UK; sulbactam, Pfizer, New York, NY,
USA; amikacin, Bristol-Myers Squibb, USA; gen-
tamicin, Schering Plough, Manati, PR, USA; tobra-
mycin, Eli-Lilly, Indianapolis, IN, USA; netilmicin,
Schering Plough, USA; rifampicin, Gruppo Lepetit
SpA, Milano, Italy.
Bacteriocin typing
Bacteriocin typing for all K. pneumoniae clinical
isolates was performed by A. Bauernfeind accord-
ing to procedures described previously [10].
Molecular typing
Molecular typing was performed by REP-PCR, a
PCR-based DNA fingerprinting technique which
uses oligonucleotide primers based on the highly
conserved repetitive extragenic palindromic (REP)
repeated DNA element [11]. Bacterial genomic
DNAs were isolated from 1.5-mL samples of the
overnight culture with the QIAamp DNA Mini Kit
(QIAGEN GmbH, Hilden, Germany) and were
used as templates for PCR. PCR was performed
with REP-1 (50-III-GCG CCG ICA TCA GGC-30)
and REP-2 (50-ACG TCT TAT CAG GCC TAC-30)
primers derived from repetitive extragenic palin-
dromic (REP) elements. The reaction mixture was
subjected to initial denaturation (95 8C, 7 min),
followed by 30 cycles of denaturation (94 8C,
1 min), annealing (40 8C, 1 min) and extension
(65 8C, 8 min) and then a single final extension
(65 8C, 16 min). Amplified DNA segments were
visualized after running samples on 2% agarose
gels for 2 h. The fingerprints were compared
visually for the reproducible portion of the pattern
below the 6.6-kb size marker. Patterns were consid-
ered different if they differed by one or more amp-
lification bands, regardless of the band intensity.
Susceptibility studies
Antibiotic susceptibi1ity testing was performed
by a disk diffusion method on Mueller–Hinton
agar [12]. The strains were further examined by
the double-disk synergy test (DDST) for the pre-
sence of extended-spectrum b-lactamases [13,14].
Clavulanic acid and sulbactam (10 mg)were spot-
ted on filter disks (6-mm diameter) and placed at
the top of antibiotic disks (ceftazidime, ceftriax-
one, cefotaxime and aztreonam). A 5-mm increase
in zone diameter for either antimicrobial agent,
tested in combination with clavulanic acid or sul-
bactam, compared to its zone when tested alone,
confirmed an ESBL-producing K. pneumoniae strain.
Minimal inhibitory concentration values (MICs)
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for ceftazidime, aztreonam, cefotaxime, ceftriax-
one, imipenem, meropenem and aminoglycosides
were determined in MH broth according to the
guidelines of the National Committee for Clinical
Laboratory Standards [15].
Transfer of resistance
Conjugation experiments were performed by the
broth culture mating technique, with E. coli RC85
R– K12 strain (rifampicin resistant, MIC> 128 mg/
L) used as recipient. Recipient and donor strains
were inoculated into brain–heart infusion broth
and incubated at 37 8C for 4 h. They were then
mixed in a ratio 10:1 (recipient/donor) and incu-
bated at 37 8C for a further 6 h. Transconjugants
were selected on MacConkey Agar, supplemented
with rifampicin (128 mg/L) to inhibit the growth
of the donor strain, and ceftazidime (16 mg/L) to
inhibit the growth of the recipient strain.
Determination of aminoglycoside resistance
mechanisms
The determination was made by disk suscep-
tibility testing for gentamicin, amikacin, tobramy-
cin, netilmicin, neomycin, kanamycin, SCH 21420,
apramicin, fortimicin, SCH 21562, SCH 21561 and
SCH 22591 (aminoglycoside resistance patterns—
AGRPs) and DNA probe analysis with probes of
ANT(200)-Ia, AAC(3)-I, AAC(3)-Va, AAC(60)-Ib,
AAC(60)-Ic, APH(30)-I, ANT(40)-II, APH(30)-VIa and
APH(200)þ (60) aminoglycoside resistance genes,
which were kindly provided by G. Miller [16,17].
Hybridization experiments
The DNA probes were purified twice through
agarose gels after double digestion with appro-
priate restriction endonucleases. The fragments
were then labeled with digoxigenin (Boehringer
Mannheim, Mannheim, Germany). Probe labeling,
DNA hybridization (dot blotting) and detection of
hybridization were done using the DIG-Non
Radioactive Labelling and Detection Kit (Boehrin-
ger Mannheim) as recommended by the manufac-
turer, on S & S Nytran-N membranes.
b-Lactamase preparation
b-Lactamases were obtained from the clinical
isolates or from transconjugants after centrifuga-
tion of sonicated cells. Cultures were performed
in trypticase soy broth containing subinhibitory
concentrations of ceftazidime (1–2 mg/L). Cells
were grown aerobically at 37 8C until the late
exponential phase, collected by centrifugation,
resuspended in 0.1% glycine (1/30 of the original
culture volume), and disrupted by sonication (six
times for 30 s each). The supernatant obtained after
centrifugation at 22 000  g for 45 min to remove
the cell debris represented the crude extract. b-
Lactamase activity was revealed by adding 5mL of
crude bacterial extract to 30 mL of a 500 mg/L
solution of the chromogenic cephalosporin nitro-
cefin (Glaxo Wellcome).
Analytic isoelectric focusing
Sonic extracts prepared as described above were
applied on filter paper strips to commercially
obtained polyacrylamide gels containing ampho-
lines with pH ranges of 3.5–10 (LKB Products,
Bromma, Sweden). Electrofocusing was done by
the procedure recommended by the manufacturer,
using the LKB 2117 Multiphor apparatus. As refer-
ence strain for b-lactamase determination, the
SHV-5 (pI 8.2) donor K. pneumoniae 160 was used
[8]. Enzyme bands were visualized in the gels by
the use of nitrocefin.
Hydrolysis of b-lactam antibiotics
b-Lactamase activity was determined spectro-
photometrically in 50 mM sodium phosphate
buffer, pH 7.0, at 30 8C, with a double-beam spec-
trophotometer (Hitachi model 150–20). The con-
centration of each antibiotic substrate was 100 mM.
The wavelength of maximal absorption for each
antibiotic was first determined. Then the abs-
orption of the non-hydrolyzed antibiotic in the
hydrolysis mixture was measured, and the hydro-
lysis activity of each enzyme was determined in
relation to the activity it had in 100 mM ampicillin
(100%). The hydrolysis of b-lactam antibiotics was
attempted also with the microbiological method
described by Bauernfeind et al. [18], according to
which polyacrylamide gel, after the isoelectric
focusing, is overlaid with a first layer of agar
containing the b-lactam antibiotic (ceftazidime,
aztreonam or cefotaxime) and with a second layer
of tryptic soy agar mixed with an E. coli sus-
ceptible strain. After overnight incubation, the
positive result of hydrolysis was shown by the
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growth of E. coli colonies around the band of the
enzyme.
Plasmid DNA preparation
A rapid procedure according to Kado and Liu was
performed [19]. Large-scale preparation was per-
formed with alkaline lysis according to Maniatis
et al. [20]. As reference strain for plasmid DNA
isolation, E. coli strain MXR, containing plasmid
pULB113 (68 kb), was used [9].
Plasmid DNA restriction analysis
EcoRI (Gibco-BRL, Gaithersburg, MD, USA), Hind
III (BioLabs, Beverly, MA) and restriction endo-
nucleases were used for plasmid DNA restriction
analysis according to the manufacturer’s instruc-
tions. The digests were electrophorized on 0.8%
agarose gels, with HindIII digests of bacteriophage
lDNA and 1-kb DNA ladder as molecular size
markers.
PCR amplification and sequencing
of SHV gene
An 865-bp sequence of the SHV gene was
PCR amplified using the oligonucleotide pri-
mers 50-ATG CGT TAT ATT CGC CTG TG-30 and
50-GTT AGC GTT GCC AGT GCT CG-30. Chromo-
somal DNA was prepared by using the Qiamp
tissue kit (QIAGEN GmbH) as described by the
manufacturer. The PCR reaction mixture was initi-
ally incubated at 94 8C for 5 min, followed by 30
cycles of denaturation (60 s at 94 8C), annealing
(60 s at 56 8C) and extension (180 s at 72 8C). The
extension was completed after 7 min of incubation
at 72 8C. Reactions were carried out in a thermal
Cycler 480 (Perkin Elmer Cetus, Emeryville, CA,
USA). The nucleotide sequences of PCR-generated
amplimers were determined using the Taq
DyedeoxyTerminator Cycle sequence kit and ana-
lyzed in an automatic DNA Sequencer ABI
(Applied Biosystems, Foster City, CA, USA;
373A).
Results
The ten K. pneumoniae isolates were resistant to
ampicillin, ureidopenicillins, first-, second- and
third-generation cephalosporins (with the excep-
tion of cefoxitin, for which two strains were resis-
tant), aztreonam, co-trimoxazole, tetracyclines and
all aminoglycosides. Three of them were also re-
sistant to quinolones, and all strains remained sus-
ceptible to imipenem (Table 1), meropenem (0.25)
and combinations with b-lactamase inhibitors. The
MICs of ceftazidime (128 to >512) and aztreonam
(256 to >512) were higher than the MICs of cefo-
taxime (32–128) and ceftriaxone (32–128) (Table 1).
The impaired activities of ceftazidime, ceftriaxone,
cefotaxime and aztreonam were significantly re-
stored when they were combined with clavulanic
acid or sulbactam in the DDST. These strains were
isolated from urinary infections, pus or sputum
from different patients (one per patient), different
wards and departments, or even different hospi-
tals. The ten K. pneumoniae strains were distinct
according to bacteriocin typing (Table 1), and nine
of them were distinct according to REP-PCR (Fig-
ure 1) too. Strains 568 and 584 had different bac-
teriocin types but shared the same amplification
pattern in REP-PCR.
Ceftazidime resistance was transferred from all
clinical isolates to E. coli recipient RC85, with a
frequency ranging from 105 to 106. The E. coli
transconjugants had similar MICs to those ob-
served for parent K. pneumoniae isolates for the
extended-spectrum cephalosporins and aztreo-
nam, with the exception of cefoxitin (Table 1).
Synergism with clavulanic acid or sulbactam
was similar to that observed with the clinical
isolates. Aminoglycoside resistance was co-trans-
ferred with ceftazidime resistance to all ten iso-
lates, as well as tetracycline and co-trimoxazole
resistance, while chloramphenicol resistance was
co-transferred in two (584, 568) of five (223, 584, 11,
568, 1290) resistant strains. Ciprofloxacin resis-
tance was not transferable.
The ten K. pneumoniae isolates had similar b-
lactamase profiles as revealed by isoelectric focus-
ing (Figure 2a). There was one band with pI of 8.2
common for all strains which was also observed in
their E. coli transconjugants. The hydrolytic prop-
erties of this b-lactamase (pI 8.2) were similar to
those of SHV-5. Ceftazidimase activity was de-
monstrated by both methods used, with cef-
tazidime, cefotaxime, ceftriaxone and aztreonam
hydrolyzed as by the SHV-5 enzyme, and hydro-
lysis inhibited by clavulanic acid and sulbactam
(Figure 2b). DNA sequences of SHV genes from
the transconjugant strains were identical to that of
the SHV-5 b-lactamase gene published by Billot-
Klein et al. [21].
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Table 1 Main characteristics and susceptibility patterns to b-lactam antibiotics (MIC in mg/L) of 10 K. pneumoniae strains and their transconjugants
Antibiotics
Strain Species Bacteriocin typing Ceftazidime Ceftriaxone Cefotaxime Aztreonam Cefoxitin Imipenem MEM
41a K. pneumoniae 3, 5 >512 32 64 >512 16 1 0.25
41-tb E. coli RC85 >512 64 128 >512 4 0.25 0.25
223a K. pneumoniae 1, 3, 5, 6, 7 256 >128 64 512 >128 0.5 0.25
223-tb E. coli RC85 64 8 16 256 4 0.25 0.25
584a K. pneumoniae 3 >512 64 64 >512 16 2 0.25
584-tb E. coli RC85 512 64 64 512 8 0.25 0.25
660a K. pneumoniae 1, 7 256 32 128 >512 4 1 0.25
660-tb E. coli RC85 512 64 256 256 8 0.25 0.25
1459a K. pneumoniae 1, 2, 3, 7 128 64 32 256 8 0.5 0.25
1459-tb E. coli RC85 64 4 32 256 4 0.25 0.25
2294a K. pneumoniae 1, 3, 4, 5, 6, 7 256 32 32 512 8 0.5 0.25
2294-tb E. coli RC85 128 16 16 64 4 0.25 0.25
2573a K. pneumoniae 1, 2, 3, 5, 6, 7 256 32 32 512 2 0.5 0.25
2573-tb E. coli RC85 256 16 32 256 4 0.25 0.25
11a K. pneumoniae 1, 3 >512 32 32 >512 4 1 0.25
11-tb E. coli RC85 256 32 64 256 4 0.25 0.25
568a K. pneumoniae 0 >512 64 128 >512 8 0.5 0.25
568-tb E. coli RC85 >512 128 128 >512 4 0.25 0.25
1290a Klebsiella pneumonia 1, 3, 6 >512 64 64 >512 64 2 0.25
1290-tb E. coli RC85 >512 32 64 >512 4 0.25 0.25
RC85 E. coli 1 0.25 0.07 0.5 2 0.25 0.25
aK. pneumoniae parent strain. bE. coli transconjugant strain.
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The aminoglycoside-modifying enzymes AAC
(60)-I and AAC(3)-I were produced by all K. pneu-
moniae clinical isolates and by their E. coli trans-
conjugants, as demonstrated by the AGRP method
and DNA probe analysis. APH(30)-I was also
observed in seven donor strains and their trans-
conjugants (Table 2).
A plasmid of approximately 80 kb, with closely
related EcoRI and HindIII restriction patterns, was
isolated from all E. coli transconjugants, encoding
the SHV-5-type b-lactamase, the aminoglycoside-
modifying enzymes, and tetracycline and co-tri-
moxazole resistance. Slight differences in restriction
patterns of plasmids also encoded for APH(30)-I
were observed (Figure 3).
Figure 1 Repetitive extragenic palindromic (REP) PCR.
Lanes 1 and 13: fX174 DNA/HaeIII digest. Lane 2: PCR
control. Lanes 3–12: Amplified DNA segments of strains
11, 41, 223, 568, 584, 660, 1290, 1459, 2294 and 2573,
respectively.
Table 2 Determination of aminoglycoside-modifying en-
zymes produced by 10 K. pneumoniae clinical isolates and
their transconjugants after hybridization with 10 different
DNA probesa
Indicative
number of strain Enzymes produced
41 AAC(3)-I, AAC(60)-I, APH(30)-I
223 AAC(3)-I, AAC(60)-I
584 AAC(3)-I, AAC(60)-I, APH(30)-I
660 AAC(3)-I, AAC(60)-I, APH(30)-I
1459 AAC(3)-I, AAC(60)-I, APH(30)-I
2294 AAC(3)-I, AAC(60)-I
2573 AAC(3)-I, AAC(60)-I
11 AAC(3)-I, AAC(60)-I, APH(30)-I
568 AAC(3)-I, AAC(60)-I, APH(30)-I
1290 AAC(3)-I, AAC(60)-I, APH(30)-I
aThe correlation of the results of AGRP resistance patterns
and DNA probe analysis was 100%.
Figure 2 (a) Isoelectric focusing (pH range 3.5–9.5) of
b-lactamases. Lane 1: K. pneumoniae 160 (SHV-5). Lane 2:
K. pneumoniae clinical isolate 223. Lane 3: E. coli transcon-
jugant 223-1. Lane 4: K. pneumoniae clinical isolate 1459.
Lane 5: E. coli transconjugant 1459-1. Lane 6: K. pneumoniae
clinical isolate 2294. Lane 7: E. coli transconjugant 2294-1.
The arrow identifies a b-lactamase with a pI of 8.2. (b)
Microbiological method of hydrolysis of ceftazidime,
cefotaxime, ceftriaxone and aztreonam by b-lactamases.
Lane 1: K. pneumoniae 160 (SHV-5). Lane 2: K. pneumoniae
clinical isolate 223. Lane 3: E. coli transconjugant 223-1.
Lane 4: K. pneumoniae clinical isolate 1459. Lane 5: E. coli
transconjugant 1459-1. Lane 6: K. pneumoniae clinical
isolate 2294. Lane 7: E. coli transconjugant 2294-1. The
arrow identifies the hydrolysis of ceftazidime, cefotaxime,
ceftriaxone or aztreonam by the b-lactamase with
pI 8.2.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8, 579–588
584 Clinical Microbiology and Infection, Volume 8 Number 9, September 2002
D I S C U S S I O N
Extended-spectrum cephalosporins are often used
as primary agents for the treatment of severe,
mostly nosocomial, infections. However, soon after
the introduction of the newer extended-spectrum
cephalosporins into clinical practice, the emer-
gence of resistance with subsequent therapeutic
failures was observed. Extended-spectrum enzy-
mes were first recognized in Europe in 1983 [22],
but have since been reported in many countries
[7,8,22–27]. The prevalence of strains producing
extended-spectrum b-lactamases is increasing
worldwide, and K. pneumoniae is by far the most
common species in which these enzymes have been
recognized. Plasmids responsible for extended-
spectrum b-lactamase production tend to be large
(80 kb or more in size) and tend to carry resistance
to several agents [7,28–30], an important limitation
to be taken into consideration in the design of
treatment alternatives. Curiously, none of these
enzymes has been shown to be transposable [28],
although TEM-1 and TEM-2 can be transposon
encoded [30,31]. The usual transmissibility of the
responsible plasmids, however, allows resistance
to spread readily to other pathogens, so that
extended-spectrum enzymes have been found
not only in E. coli, Klebsiella spp., Pseudomonas aerug-
inosa, Citrobacter freundii and Enterobacter cloacae, but
also in Enterobacter aerogenes, Levinea malonatica,
Morganella morganii, Salmonella spp. and Serratia
marcescens [29,32]. In many outbreaks, related plas-
mids from isolates at a single hospital encoded
different extended-spectrum enzymes, as though
sequential mutations were occurring in a common
b-lactamase gene [33,34]. For these reasons, we
examined ten multiresistant K. pneumoniae clinical
isolates derived from different wards, departments
or hospitals in Greece to determine their resistance
mechanisms to third-generation cephalosporins,
aztreonam and aminoglycosides. It should be
pointed out that recent resistance rates of K. pneu-
moniae strains to ceftazidime ranged from 35% to
83% and to amikacin from 22% to 61% (WHONET
Greece, 1999; A. Vatopoulos, personal communi-
cation). There is no doubt that, in order to solve the
difficult therapeutic problems with infections
caused by multiresistant bacteria and by K. pneu-
moniae in particular in Greek hospitals, it is vital to
investigate their underlying resistance mechan-
isms to several antimicrobials, since empirical
treatment of nosocomial infections is very often
initiated with a combination of a broad-spectrum
cephalosporin and an aminoglycoside.
Nine of the ten strains examined were distinct,
as confirmed by bacteriocin typing and REP-PCR,
suggesting that one resistant clone has not been
spread, but rather, multiresistant plasmids har-
boring the bla gene and genes encoding for amino-
glycoside-modifying enzymes between different
strains of enterobacteria have spread.
The enzyme isolated with a pI of 8.2, with
hydrolytic activity against ceftazidime, cefotax-
ime, ceftriaxone and aztreonam, that is inhibited
by clavulanic acid and sulbactam, suggests a close
relationship with the SHV-5 b-lactamase. Sequen-
cing of the blaSHV genes showed that the strains
produced SHV-5, and not one of the recently
described b-lactamases that have the same pI,
i.e. SHV-9, SHV-10 [5], or SHV-12 [35]. SHV-5 is
one of the most frequently encountered ESBLs
produced by K. pneumoniae strains worldwide
[1]. It was first reported in Chile [8] as well as in
France (CAZ-4 b-lactamase) [36], and has already
been described in Greece [7]. Gutmann et al. [8]
reported that SHV-5 was encoded by a plasmid of
150 kb that was self-transferable to other K. pneu-
moniae strains, but not to E. coli. It was not reported
whether this plasmid carried resistance genes for
non-b-lactam antibiotics. The CAZ-4 enzyme, iso-
lated in Clermont-Ferrand Hospital in France
[36,37], was also encoded by a 150-kb plasmid,
Figure 3 EcoRI restriction patterns of the transferred
plasmid isolated from E. coli transconjugants. Lane 1:
lDNA/HindIII digest. Lanes 2–11: EcoRI digests of plasmid
isolated from strains 1290-1, 2294-1, 2573-1, 41-1, 223-1,
584-1, 1459-1, 11-1, 568-1, 1201-1. Lane 12: 1-kb DNA
ladder.
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but was transferable to E. coli at a 1ow frequency
(106) and co-transferred resistance to amikacin,
kanamycin, netilmicin, tobramycin, chloramphe-
nicol and sulfonamides. Vatopoulos et al. [7]
reported that the SHV-5-type enzyme isolated
from Greek K. pneumoniae isolates was encoded
by related 91-kb plasmids that were easily self-
transferred to E. coli, and some of them also
encoded resistance to aminoglycosides tobramy-
cin, amikacin and netilmicin. Shannon et al. re-
ported another SHV-5-type b-lactamase produced
by a K. pneumoniae strain isolated from a patient
from Greece, which was encoded by a 90–100-MDa
(137–152-kb) plasmid, and which also encoded
lactose fermentation, but not resistance to tobra-
mycin, sulfamethoxazole or trimethoprim.
The aminoglycoside resistance mechanisms in
K. pneumoniae clinical isolates comprise the pro-
duction of the aminoglycoside-modifying enzymes
AAC(60)-I, mediating resistance to gentamicin,
tobramycin, netilmicin and amikacin, and AAC
(3)-I, mediating resistance to gentamicin and siso-
mycin, and were encoded in all isolates and their
E. coli transconjugants. APH(30)-I, mediating resis-
tance to kanamycin and neomycin, was also pro-
duced by seven strains and their transconjugants.
Studies on the aminoglycoside resistance mechan-
isms in aminoglycoside-resistant isolates under-
taken between 1988 and 1993 in several countries
showed a much greater incidence of complexity of
those mechanisms than did earlier studies [38,39].
The resistance rates among aminoglycoside-resis-
tant Klebsiella species to the clinically available
aminoglycosides in these surveys were quite dif-
ferent from those observed in earlier surveys. As
expected, in the earliest surveys, rates of resistance
to gentamicin and tobramycin were quite high,
and resistance rates to netilmicin, amikacin and
isepamicin were quite low. Later surveys in Eur-
ope, after the latter aminoglycosides had been
frequently used, showed higher netilmicin resis-
tance. In Greek hospitals, where amikacin and
netilmicin usage (40% and 50%, respectively)
was very high [40], the incidence of AAC(60)-I
(tobramycin, netilmicin, amikacin, dibekacin, and
kanamycin) as a single aminoglycoside resistance
mechanism was 8.9%, but a single combination of
AAC(60)-I with AAC(3)-I (gentamicin) was very
common (59.5%), especially in the 14 Greek hos-
pitals and one Turkish hospital surveyed [41]. This
combination occurred in many different types of
Enterobacteriaceae in each of the individual Greek
hospitals, where it seemed to be acting as a plas-
mid epidemic. It was almost always found toge-
ther with APH(30)-I (kanamycin and neomycin).
Our results agree with those findings, and a com-
bination of the previous three enzymes is estab-
lished in the transferable plasmid examined. The
restriction patterns of the plasmid isolated from
each donor strain and its E. coli transconjugant
were identical for the strains harboring the
aph(3)-I gene, showing extended homology in their
endonuclease restriction analysis. Isolates expres-
sing no APH(30)-I activity (three of ten) showed
small differences in their restriction patterns com-
pared to the previous ones.
Co-trimoxazole resistance in the K. pneumoniae
clinical isolates examined here is plasmid encoded,
and was co-transferred in E. coli transconjugants
with third-generation cephalosporin and amino-
glycoside resistance.
The presence of various multiresistant self-
transferable plasmids in K. pneumoniae strains iso-
lated in Greek hospitals has been reported in
previous studies [7], along with the production
of the SHV-5-type b-lactamase. This study reports,
for the first time, the production of aminoglyco-
side-modifying enzymes encoded by genes har-
bored in the same self-transferable plasmid as that
harbors the b-lactamase SHV-5.
In conclusion, the results of the present study
indicate clearly that self-transferable plasmids,
which encoding a variety of resistance genes, seem
to have become established in K. pneumoniae in
Greece. Genes that encode (1) the extended-spec-
trum SHV-5 b-lactamase causing unusually high
resistance to ceftazidime and aztreonam; (2) ami-
noglycoside-modifying enzymes such as AAC(60)-
I, AAC(3)-I and APH(3)-I causing resistance to all
clinical available aminoglycosides, and (3) co-tri-
moxazole and tetracycline resistance, are all located
in one plasmid. Owing to the high in vitro fre-
quency of transfer of the R-factor carrying the
previous genes, its dissemination in vivo must
be anticipated. Accordingly, the excessive con-
sumption of third-generation cephalosporins in
Greek hospitals, either as monotherapy or as com-
bination therapy, should be restricted. The latter
indication is based on the results of several studies
which proved that reduction in overuse or misuse
of ceftazidime was followed by a remarkable
reduction in resistance rates of K. pneumoniae
strains to cephalosporins [42,43]. As the use of
aminoglycosides, at least in Greece, is limited
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because of the fear of nephrotoxicity, they are not,
therefore, considered to perpetuate resistance to
advanced cephalosporins.
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